Insulet Corp
PODD285.170USD
-3.230-1.12%
Market hours （ET）Quotes delayed by 15 min
20.07BMarket Cap
49.89P/E TTM
More Details of Insulet Corp Company
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Company Info
Ticker SymbolPODD
Company nameInsulet Corp
IPO dateMay 15, 2007
Founded at2000
CEOMs. Ashley Mcevoy
Number of employees3900
Security typeOrdinary Share
Fiscal year-endMay 15
Address100 Nagog Park
CityACTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code01720-3440
Phone19786007000
Websitehttps://www.omnipod.com
Ticker SymbolPODD
IPO dateMay 15, 2007
Founded at2000
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
27.70K
+2.89%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
16.23K
+5.03%
Mr. Eric Benjamin
Mr. Eric Benjamin
Executive Vice President, Chief Product and Customer Experience Officer
Executive Vice President, Chief Product and Customer Experience Officer
14.73K
--
Ms. Ashley Mcevoy
Ms. Ashley Mcevoy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
9.54K
+238500.00%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
5.24K
+17.43%
Ms. Lauren Budden
Ms. Lauren Budden
Chief Accounting Officer, Group Vice President, Corporate Controller
Chief Accounting Officer, Group Vice President, Corporate Controller
5.22K
+17.01%
Mr. Prem Singh
Mr. Prem Singh
Senior Vice President - Global Operations
Senior Vice President - Global Operations
4.25K
-20.11%
Ms. Laetitia Cousin
Ms. Laetitia Cousin
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance
3.58K
+24.38%
Dr. Luciana Borio, M.D.
Dr. Luciana Borio, M.D.
Independent Director
Independent Director
3.09K
-13.48%
Mr. Timothy C. (Tim) Stonesifer
Mr. Timothy C. (Tim) Stonesifer
Independent Director
Independent Director
2.89K
+36.78%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
27.70K
+2.89%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
16.23K
+5.03%
Mr. Eric Benjamin
Mr. Eric Benjamin
Executive Vice President, Chief Product and Customer Experience Officer
Executive Vice President, Chief Product and Customer Experience Officer
14.73K
--
Ms. Ashley Mcevoy
Ms. Ashley Mcevoy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
9.54K
+238500.00%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
5.24K
+17.43%
Ms. Lauren Budden
Ms. Lauren Budden
Chief Accounting Officer, Group Vice President, Corporate Controller
Chief Accounting Officer, Group Vice President, Corporate Controller
5.22K
+17.01%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
By BusinessUSD
Name
Revenue
Proportion
U.S.Omnipod
401.70M
70.60%
International Omnipod
152.40M
26.78%
Drug Delivery
14.90M
2.62%
By RegionUSD
Name
Revenue
Proportion
United States
416.60M
73.22%
All Other
152.40M
26.78%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
U.S.Omnipod
401.70M
70.60%
International Omnipod
152.40M
26.78%
Drug Delivery
14.90M
2.62%
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.28%
Fidelity Management & Research Company LLC
10.13%
Capital Research Global Investors
8.64%
BlackRock Institutional Trust Company, N.A.
6.20%
State Street Global Advisors (US)
4.30%
Other
58.46%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
12.28%
Fidelity Management & Research Company LLC
10.13%
Capital Research Global Investors
8.64%
BlackRock Institutional Trust Company, N.A.
6.20%
State Street Global Advisors (US)
4.30%
Other
58.46%
Shareholder Types
Shareholders
Proportion
Investment Advisor
67.95%
Investment Advisor/Hedge Fund
23.98%
Hedge Fund
3.39%
Research Firm
2.94%
Pension Fund
1.77%
Sovereign Wealth Fund
1.43%
Bank and Trust
1.38%
Individual Investor
0.29%
Private Equity
0.10%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
1531
72.76M
103.41%
-3.63M
2025Q1
1569
72.82M
103.50%
-3.52M
2024Q4
1508
72.57M
103.34%
-4.94M
2024Q3
1436
73.14M
104.31%
-3.15M
2024Q2
1408
72.17M
103.04%
-3.02M
2024Q1
1350
71.60M
102.26%
-3.12M
2023Q4
1320
72.91M
104.42%
-1.52M
2023Q3
1254
72.05M
103.19%
-4.06M
2023Q2
1223
73.42M
105.35%
-3.44M
2023Q1
1206
74.71M
107.20%
-300.49K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
8.64M
12.28%
+178.96K
+2.12%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.13M
10.13%
+45.85K
+0.65%
Mar 31, 2025
Capital Research Global Investors
6.08M
8.64%
-1.37M
-18.40%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.36M
6.2%
+115.38K
+2.72%
Mar 31, 2025
State Street Global Advisors (US)
3.02M
4.3%
+49.05K
+1.65%
Mar 31, 2025
Baillie Gifford & Co.
2.25M
3.2%
-104.93K
-4.45%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.87M
2.66%
+90.07K
+5.06%
Mar 31, 2025
ClearBridge Investments, LLC
1.48M
2.1%
+73.68K
+5.24%
Mar 31, 2025
Fidelity International
1.29M
1.83%
-146.07K
-10.21%
Mar 31, 2025
American Century Investment Management, Inc.
1.15M
1.64%
+297.73K
+34.83%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Langar Global HealthTech ETF
6.37%
Global X HealthTech ETF
4.95%
Fidelity Digital Health ETF
4.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
4.85%
Goldman Sachs Future Health Care Equity ETF
4.69%
Congress SMid Growth ETF
3.43%
Nuveen ESG Mid-Cap Growth ETF
2.85%
iShares Health Innovation Active ETF
2.73%
FT Raymond James Multicap Growth Equity ETF
2.64%
First Trust Health Care Alphadex Fund
2.61%
View more
Langar Global HealthTech ETF
Proportion6.37%
Global X HealthTech ETF
Proportion4.95%
Fidelity Digital Health ETF
Proportion4.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion4.85%
Goldman Sachs Future Health Care Equity ETF
Proportion4.69%
Congress SMid Growth ETF
Proportion3.43%
Nuveen ESG Mid-Cap Growth ETF
Proportion2.85%
iShares Health Innovation Active ETF
Proportion2.73%
FT Raymond James Multicap Growth Equity ETF
Proportion2.64%
First Trust Health Care Alphadex Fund
Proportion2.61%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
